Clinical TrialID 29

Ginkgo Biloba Extract in the Treatment of Schizophrenia

NCT05258123

Schizophrenia

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Trial: 1Herb: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final clinical_trial record.

Clinical Trial Id
29
Evidence Id
29
Core Evidence Id
29
Source Clinical Trial Id
24
Herb2 Clinical Trial Id
HBCT000024
Nct Id
NCT05258123
Title
Ginkgo Biloba Extract in the Treatment of Schizophrenia
Status
Completed
Phase
Study Result
No
Study Condition
Schizophrenia
Study Type
Interventional
Study Design
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT
Intervention
DRUG: Ginkgo Biloba Extract|DRUG: Placebo oral tablet
Intervention Allocation
Randomized
Intervention Model
Parallel
Intervention Mask
Single
Intervention Purpose
Treatment
Gender
All
Age
Adult
Enrollment
100
Outcome Measure
clinical symptoms, symptoms assessed on PANSS, 12 weeks|cognitive functioning, cognitive functioning assessed on RBANS, 12 weeks
Sponsor Collaborator
Beijing HuiLongGuan Hospital
Funded By
OTHER
Location
Beijing HuiLongGuan Hospital, Beijing, 100096, China
Other Id
CASPsy4
Start Date
2017-05-15
Primary Completion Date
2018-06-12
Completion Date
2018-08-15
First Posted
2022-02-28
Results First Posted
Last Update Posted
2022-02-28
Study Document
Study Url
https://clinicaltrials.gov/study/NCT05258123
Title Cn
Title En
Ginkgo Biloba Extract in the Treatment of Schizophrenia
Bilingual Status
semi_complete